🟢 Moderna is trading 4.1% up today as shares stabilize following last week's earnings-driven selloff

Moderna is trading 4.07% up now at $57.05 as shares stabilize following last week’s earnings-driven selloff and norovirus trial disappointment.

• Investors are reassessing the Q2 report, which featured a revenue beat, a smaller-than-expected loss per share, and a pivot toward cost-cutting.
• The company reiterated its 2026 growth guidance, helping to offset concerns regarding the Phase 3 setback for its mRNA-1403 norovirus candidate.